Oventus signs further material agreements with two US sleep groups to deliver O2Vent® Sleep Treatment Platform to patients with sleep apnoea
Key points:
-
Agreements signed with US sleep groups, Delaware Sleep Disorder Centres and Reliable Respiratory, to supply dental sleep medicine solutions across a total of 10 facilities
-
Adds to news of first agreements signed in June and July with sleep groups in Canada and the US for the Oventus O2Vent® Sleep Treatment Platform which treats obstructive sleep apnoea (OSA)
-
Oventus expects to secure further agreements across its key target markets in the US, Canada and Australia over the next 12-24 months, with a view to significant scaling through to the end of CY2019 and CY2020; negotiations ongoing with multiple groups
-
Oventus is strongly positioned to scale sales substantially following the announcement of a capital raise on 26 July: Placement of A$7m and Entitlement Offer launched to raise A$2.3m from existing shareholders
For further information please download the attached PDF:
Download this document
